The CHM.AX stock surged 33.33% in pre-market trade to A$0.002 on 04 Mar 2026, making Chimeric Therapeutics Limited a top gainer on the ASX. Volume climbed to 1,609,843.00 shares versus a 50-day average, driving a short squeeze in this microcap biotech. The move follows renewed investor interest in Chimeric’s early-stage clinical programs and leaves the stock well off its A$0.009 year high, keeping volatility and upside potential high for short-term traders.

Why CHM.AX stock jumped pre-market

Pre-market buying pushed CHM.AX from A$0.0015 to A$0.002, a +33.33% one-day change. One clear driver was renewed attention on Chimeric’s phase I programs, which often prompt re-rating in small-cap biotech names. The trade shows high short-term interest: current volume 1,609,843.00 is significant versus the average 5,982,360.00, creating a tight intra-day supply picture.

Key drivers and recent news for Chimeric Therapeutics (CHM.AX)

Chimeric Therapeutics (CHM.AX) is advancing multiple cell therapy candidates in oncology, including CHM 0201 and CHM 1101 in phase I trials. Clinical-readout speculation and sector momentum in Healthcare helped lift the stock. The company website lists ongoing programs and pipeline details; investors track milestone timing closely because small updates can move price materially source.

Financial snapshot and valuation metrics for CHM.AX stock

At the pre-market price A$0.002, Chimeric’s market cap is A$8,837,407.00 with 4,418,707,619.00 shares outstanding. Reported EPS is -0.01 and P/E is -0.20, reflecting negative earnings typical for clinical-stage biotech. Key ratios show price-to-sales 2.48 and EV/sales 1.78, while cash per share is 0.00077. The balance shows low cash runway risk now, but continued R&D spend (R&D/revenue 1.65x) keeps dilution risk high.

Technical view, trading metrics and sector context for CHM.AX stock

Technically CHM.AX trades below its 200-day average; the 50-day average sits near A$0.002 and the 200-day near A$0.003. Relative volume is elevated at 4.74, and RSI sits near 49.83, indicating neutral momentum after a sharp move. In the Healthcare sector, peers show mixed short-term performance, so CHM.AX’s spike is stock-specific and volume-driven rather than broad sector strength.

Meyka AI grade and analyst summary for CHM.AX

Meyka AI rates CHM.AX with a score out of 100: 70 / B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model flags strong clinical potential against weak liquidity and recurring losses. Investors should treat the grade as data-driven context, not financial advice.

Risks, catalysts and what traders should watch

Primary catalysts are clinical milestones, trial enrollment updates and partnering news; any positive readout can re-rate CHM.AX substantially. Key risks include limited liquidity, continued operating losses, and potential equity raises. Watch day-range and average volume: day high and low are both A$0.002, year high A$0.009 and year low A$0.002, which highlights compressed price action until a clear news event expands trading range.

Final Thoughts

CHM.AX stock is a volatile microcap biotech that moved +33.33% pre-market to A$0.002 on 04 Mar 2026 as traders reacted to pipeline interest and thin liquidity. Short-term upside is news-driven; the stock trades well below its year high A$0.009 and above a rounded year low A$0.002, so momentum can flip quickly. Meyka AI’s forecast model projects a 12-month base-case target of A$0.006, implying +200.00% versus the current price, and a short-term target of A$0.004 (+100.00%). A conservative bear scenario puts a downside near A$0.001 (-50.00%). Forecasts are model-based projections and not guarantees. Use stop limits, size positions carefully, and monitor clinical updates or financing moves that would materially change valuation assumptions. For more company detail see the company site and profile source and our stock page at Meyka AI source.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.